CANY
JAZZ icon

Caxton Associates (New York)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Caxton Associates (New York)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,941
Closed -$738K – 492
2019
Q4 		$738K Buy
4,941
+1,667
+51% +$227K 0.1% 119
2019
Q3 		$420K Buy
+3,274
New +$439K 0.08% 169
2019
Q1 		– Sell
-1,823
Closed -$226K – 440
2018
Q4 		$226K Buy
+1,823
New +$270K 0.04% 231

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Caxton Associates (New York)'s JAZZ Position: Q1 2020 in Review

Caxton Associates (New York) sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 4,941 shares — an estimated $738K sold.

Caxton Associates (New York) first reported a position in JAZZ in Q4 2018 and held it in 3 quarters. The position peaked at $738K in Q4 2019. 408 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

  • Caxton Associates (New York) reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 4,941 Jazz Pharmaceuticals shares in Q1 2020, an estimated $738K.
  • Caxton Associates (New York) first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Caxton Associates (New York)'s Jazz Pharmaceuticals position peaked at $738K in Q4 2019.
  • 408 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Caxton Associates (New York)'s 13F filing for Q1 2020, filed 15 May 2020.